register

News & Trends - Pharmaceuticals

Shedding light on silent suffering of over 7 million Australians

Health Industry Hub | October 27, 2023 |

Pharma News: A staggering one in three Australians grapples with debilitating musculoskeletal conditions, such as back pain, arthritis, and a multitude of other painful muscle, bone, and joint ailments, according to Musculoskeletal Australia (MSK). The most disheartening aspect? Many of these individuals suffer in silence.

MSK CEO, Helen Jentz, is determined to change this narrative. She revealed that a new survey, scheduled to open on October 31, 2023, aims to “lift the cloak of invisibility” and provide those affected with a stronger platform to voice their concerns and struggles.

“The 2020 survey painted a very clear and confronting picture of the painful reality of life with a musculoskeletal condition,” Ms Jentz expressed. “Because these conditions and their impacts are not always seen or discussed, those living with them feel completely invisible. Musculoskeletal Australia exists to improve the lives of Australians who are negatively impacted by these conditions, and this survey is just one of the ways we do this.”

This initiative follows Australia’s most extensive national survey of people living with musculoskeletal conditions in 2020. The 2023 edition seeks to build upon the earlier findings, allowing researchers to map changes over time and delve into the financial hardships endured by those afflicted with these conditions.

The survey is set to launch on October 31, coinciding with Musculoskeletal Australia’s annual “Rattle Ya Bones Day,” and will remain open for responses until December 31.

Musculoskeletal conditions are, according to the Australian Institute of Health and Welfare (AIHW), the third highest contributor to the national non-fatal burden of disease in the country. These conditions, unbeknownst to many, do not discriminate and can profoundly impact a person’s life across the years.

Musculoskeletal Australia has joined forces with the Australian Rheumatology Association and Painaustralia. Their aim is to “shed light on the experiences, challenges, and needs of these consumers and to foster understanding and advocacy,” as stated by Australian Rheumatology Association CEO Tracey Rudd. Their collective goal over the next eight weeks is to gather over 5,000 responses, uniting individuals and organizations to shape a brighter future for those battling musculoskeletal and inflammatory conditions.

Painaustralia CEO Giulia Jones welcomed the national survey, emphasizing their eagerness to learn from people living with chronic pain conditions, including musculoskeletal conditions.

Ms Jentz explained that this collaboration will refocus musculoskeletal conditions as a national health priority. “It is time we pulled off the ‘cloak of invisibility’ to get a clear picture of the impact musculoskeletal conditions have so we can deliver real, systemic change and life-altering solutions for these invisible Australians.”

The 2023 National Musculoskeletal Consumer Survey will be accessible on the Musculoskeletal Australia website from October 31 to December 31, 2023. This initiative strives to empower individuals and highlight the struggles of those often overshadowed by their invisible pain.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

APAC medtech company scores TGA approval in heart disease

APAC medtech company scores TGA approval in heart disease

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics News: An Asia Pacific medtech company has announced that its flagship drug-eluting stent (DES) has received regulatory […]

More


News & Trends - MedTech & Diagnostics

New state-based pilot to back home-grown medtech innovation

New state-based pilot to back home-grown medtech innovation

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics: In a bid to enhance opportunities for local medtech manufacturers to sell to health services, a connected […]

More


News & Trends - Pharmaceuticals

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Health Industry Hub | October 4, 2024 |

Pharma News: Ferring Pharmaceuticals has announced results from a new study, which provides the first real-world evidence supporting the efficacy […]

More


News & Trends - Pharmaceuticals

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Health Industry Hub | October 4, 2024 |

Pharma News: Australian women are calling for more accurate information about their contraceptive options, with 70% feeling inadequately educated about […]

More


This content is copyright protected. Please subscribe to gain access.